[1] Lanpher B,Brunetti-Pierri N,Lee B.Inborn errors of metabolism:the flux from Mendelian to complex diseases[J].Nat Rev Genet,2006,7:449-460. [2] Gambello MJ,Li H.Current strategies for the treatment of inborn errors of metabolism[J].J Genet Genomics,2018,45(2):61-70. [3] 杨艳玲,韩连书.单纯型甲基丙二酸尿症饮食治疗与营养管理专家共识[J].中国实用儿科杂志,2018,33(7):481-486. [4] 中华医学会儿科学分会内分泌遗传代谢学组,中华预防医学会中华预防医学会出生缺陷预防与控制专业.高苯丙氨酸血症的诊治共识[J].中华儿科杂志,2014,52(6):420-425. [5] Boy N,Muhlhausen C,Maier EM,et al.Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I:second revision[J].J Inherit Metab Dis,2017,40:75-101. [6] O′Kane RL,Vina JR,Simpson I,et al.Cationic amino acid transport across the blood-brain barrier is mediated exclusively by system y+[J].Am J Physiol Endocrinol Metab,2006,291:E412-419. [7] Ho G,Christodoulou J.Phenylketonuria:translating research into novel therapies[J].Transl Pediatr,2014,3:49-62. [8] Singh RH,Cunningham AC,Mofidi S,et al.Updated,web-ba sed nutrition management guideline for PKU:an evidence and consensus based approach[J].Mol Genet Metab,2016,118:72-83. [9] Vockley J,Burton B,Berry GT,et al.UX007 for the treatment of long chain-fatty acid oxidation disorders:safety and efficacy in children and adults following 24 weeks of treatment[J].Mol Genet Metab,2017,120:370-377. [10] Larochelle J,Alvarez F,Bussieres JF,et al.Effect of nitisin one (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec[J].Mol Genet Metab,2012,107:49-54. [11] Häberle J,Burlina A,Chakrapani A,et al.Suggested guidelines for the diagnosis and management of urea cycle disorders:first revision[J].J Inherit Metab Dis,2019,42(6):1192-1230. [12] Matoori S,Leroux JC.Recent advances in the treatment of hyperammonemia[J].Adv Drug Deliv Rev,2015,90:55-68. [13] Laemmle A,Stricker T,Häberle J.Switch from sodium phenylbutyrate to glycerol phenylbutyrate improved metabolic stability in an adolescent with ornithine transcarbamylase deficiency[J].JIMD Rep,2017,31:11-14. [14] Stacpoole PW,Nagaraja NV,Hutson AD.Efficacy of dichloroacetate as a lactate-lowering drug[J].J Clin Pharmacol,2003,43(7):683-691. [15] Fouque F,Brivet M,Boutron A,et al.Differential effect of DCA treatment on the pyruvate dehydrogenase complex in patients with severe PDHC deficiency[J].Pediatr Res,2003,53(5):793-799. [16] Concolino D,Deodato F,Parini R.Enzyme replacement the rapy:efficacy and limitations[J].Ital J Pediatr,2018,44(Suppl 2):120. [17] Lachmann RH.Treating lysosomal storage disorders:What have we learnt? [J].J Inherit Metab Dis,2020,43(1):125-132. [18] Hydery T,Coppenrath VA.A comprehensive review of peg valiase,an enzyme substitution therapy for the treatment of phenylketonuria[J].Drug Target Insights,2019,13:1-8. [19] Hoskins JA,Holliday SB,Greenway AM.The metabolism of cinnamic acid by healthy andphenylketonuric adults:a kinetic study [J].Biomed Mass Spectrom,1984,11(6):296-300. [20] Matalonga L,Gort L,Ribes A.Small molecules as therapeutic agents for inborn errors of metabolism [J].J Inherit Metab Dis,2017,40(2):177-193. [21] Mauer M,Sokolovskiy A,Barth JA,et al.Reduction of pod ocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment [J].J Med Genet,2017,54(11):781-786. [22] Alfadhel M,Al-Thihli K,Moubayed H,et al.Drug treatment of inborn errors of metabolism:a systematic review [J].Arch Dis Child,2013,98:454-461. [23] Wynn R.Stem cell transplantation in inherited metabolic di sorders [J].Hematology Am Soc Hematol Educ Program,2011,2011:285-291. [24] Oishi K,Arnon R,Wasserstein MP,et al.Liver transplantation for pediatric inherited metabolic disorders:considerations for indications,complications,and perioperative management [J].Pediatr Transplant,2016,20(6):756-769. [25] 孙丽莹,朱志军,魏林,等.肝移植治疗儿童遗传代谢性疾病42例[J].中华器官移植杂志,2017,38(6):337-342. [26] Pillai NR,Stroup BM,Poliner A,et al.Liver transplantation in propionic and methylmalonic acidemia:A single center study with literature review[J].Mol Genet Metab,2019,128(4):431-443. [27] Badell IR,Hanish SI,Hughes CB,et al.Domino liver transplantation in maple syrup urine disease:a case report and review of the literature[J].Transplant Proc,2013,45:806-809. [28] Ginocchio VM,Ferla R,Auricchio A,et al.Current status on clinical development of adeno-associated virus-mediated liver-directed gene therapy for inborn errors of metabolism[J].Hum Gene Ther,2019,30(10):1204-1210. [29] Sondhi D,Johnson L,Purpura K,et al.Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis[J].Hum Gene Ther Methods,2012,23:324-335. [30] Chandler RJ,Venditti CP.Gene therapy for methylmalonic acidemia:past,present,and future[J].Hum Gene Ther,2019,30(10):1236-1244. [31] Yin H,Xue W,Chen S,et al.Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype[J].Nat Biotechnol,2014,32:551-553. |